

PRESS RELEASE

October 13, 2016

Report from extraordinary general meeting of Saniona AB (publ)

Today, October 13, 2016, was held an extraordinary general meeting in Saniona AB (publ) ("Saniona"). The following is a summary of the decisions taken. All resolutions were passed with the requisite majority.

Decision to distribute all shares held by Saniona in the partly owned subsidiary Initiator Pharma A/S

The general meeting decided that all the company's 20,841,467 shares in the partly owned subsidiary Initiator Pharma A/S ("Initiator") shall be distributed to Saniona's shareholders and that one (1) share in Saniona shall confer the right to one (1) share in Initiator. The proposed dividend of SEK 402,751 is equal to the booked value of the Initiator shares as of September 26, 2016. This corresponds to a dividend of approximately SEK 0.0193 per outstanding share of Saniona. The record date for the dividend payment is October 21, 2016.

Determination of the number of board members and deputy board members

Due to the step down of Anker Lundemose from the board of directors, the general meeting decided that during the period until the end of the next annual general meeting the board of directors shall be composed of four board members without deputies.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

This information is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:45 CET on October 13, 2016.

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,400 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.